"
User contributions
From 2009.igem.org
(Latest | Earliest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
- 01:50, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Results [1,2])
- 01:38, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Treatement modeling (→First step : Tumour development according to time)
- 01:36, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Treatement modeling (→First step : Tumour development according to time)
- 01:32, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Tissue targeting (→Experimental method) (top)
- 01:31, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Tissue targeting (→Objective)
- 01:16, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Cancer cell line and reported gene)
- 01:15, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Cancer cell line and reported gene)
- 01:12, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Discussion)
- 01:02, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (top)
- 00:57, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Experimental approach)
- 00:45, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→The debate program)
- 00:39, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→Summarization of reflections)
- 00:01, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→Problematics related to the DVS project)
- 00:01, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→Intellectual properties)
- 00:01, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→The benefits/risks ratio)
- 23:58, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→Evolution control synthetic biology products)
- 23:55, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic
- 23:40, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic
- 20:16, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion3
- 20:15, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion3
- 20:01, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion3Fr (→Conclusion)
- 17:24, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion3Fr
- 17:21, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion3Fr
- 17:20, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion3Fr
- 15:33, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Safety (→Judging form)
- 15:29, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Safety (→Laboratory safety)
- 15:29, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Safety (→Laboratory safety)
- 14:39, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Design of the fusion protein)
- 14:38, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Design de la protéine de fusion)
- 14:36, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Design of the fusion protein)
- 14:34, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Design de la protéine de fusion)
- 14:22, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Contexte)
- 11:43, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire
- 11:39, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept2Fr (→L’internalisation du vecteur cellulaire et la libération du plasmide thérapeutique)
- 11:37, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Concept2 (→The internalization of the cell vector and the release of the therapeutic plasmid)
- 11:34, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action
- 11:29, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action
- 11:29, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action
- 11:25, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Results)
- 11:16, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Results)
- 11:13, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action
- 10:42, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Conclusions)
- 10:31, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Design de la protéine de fusion)
- 10:16, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Contexte)
- 09:45, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Conclusion [3,4,5,6,7,8,9])
- 09:43, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Conclusion [3,4,5,6,7,8,9])
- 09:43, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Conclusion [3,4,5,6,7,8,9])
- 09:42, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Conclusion [3,4,5,6,7,8,9])
- 09:41, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Résultats [1,2])
- 09:40, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (→Conclusion [3,4,5,6,7,8,9])
(Latest | Earliest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
